Annelot G.J. van Rossum

Subphenotypes of Mild-to-Moderate COPD by Factor and Cluster Analysis of Pulmonary Function, CT Imaging and Breathomics in a Population-Based Survey

Niki Fens, Annelot G.J. van Rossum, Pieter Zanen et al. · COPD Journal of Chronic Obstructive Pulmonary Disease · 2013 · 40 citations · Full text

Medicine, Toxicology, Epidemiologic Methods +16

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients

Richard D. Baird, Annelot G.J. van Rossum, Mafalda Oliveira et al. · Clinical Cancer Research · 2019 · 25 citations · Full text

Medicine, Oncology, Pharmacology +17

Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor–Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial

S.B. Vliek, Iris Noordhoek, Elma Meershoek‐Klein Kranenbarg et al. · Journal of Clinical Oncology · 2022 · 20 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)

Annelot G.J. van Rossum, Marleen Kok, Erik van Werkhoven et al. · European Journal of Cancer · 2018 · 16 citations · Full text

Medicine, Oncology, Pharmacology +17

Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy

Annelot G.J. van Rossum, Marleen Kok, Danielle McCool et al. · Oncotarget · 2017 · 14 citations · Full text

Medicine, Oncology, Pharmacology +17